Gay hookup site and app Manhunt has left the jaws of many dropped—but not in the usual way its services tend to accomplish such a feat. In what it says is an act of it honoring World AIDS Day tomorrow, Manhunt has started promoting the controversial daily HIV preventative pill Truvada as "a choice when condoms are in the way." 

Gilead's new four-in-one HIV treatment pill Stribild was listed as an "alternative" regimen to the "preferred" methods of Truvada & Atripla by the FDA in September. But new data covering a two year study being released today shows the once-daily pill is just as effective as the older kids on the block. 

The controversial practice of using the popular HIV-medication Truvada as a preventative measure for at-risk individuals has been given final approval by the Food and Drug Administration. 

Will Truvada become the gay male equivalent of a daily birth control pill?

Federal drug regulators announced today that taking the pill, Truvada, on a daily basis can help prevent contraction of HIV.

More after the jump.

In an attempt to slow the spread of HIV, California will test an HIV prevention pill, utilizing “high-risk” individuals as volunteer test subjects.

Details after the jump.

San Francisco is set to make history in early 2012 when it begins offering gay men a controversial pre-exposure prophylaxis that has successfully prevented HIV transmission at high rates during clinical trials. Details follow. 

The AIDS Healthcare Foundation has launched the No Magic Pills campaign (www.nomagicpills.org), a bold warning aimed at the makers of a successful HIV medication who are attempting to test and market their drug also as a preventative tool. But not everyone in the community can get behind AHF's campaign. 

Truvada, which has been used for years to treat people with HIV, is now found to be an effective tool in preventing infection in men who have sex with men. 

From HIV Plus Magazine:

Among a study of 2,500 men who have sex with men and transgender women who have sex with men, who used the antiretroviral medication TDF/FTC, known as the brand name Truvada, were 44% less likely to become infected with the virus. Those in the study who took the pill diligently had 70% lower risk of contracting HIV than those who did not take the pill regularly. The study was published Tuesday in the New England Journal of Medicine. 

At the end of the trial, 36 people on the Pre-Exposure Prophylaxis Initiative (PrEP) regimen became infected with...